15% in trials but semaglutide has a longer safety record and is often easier to get covered
Do not change, adjust, or discontinue any medications or prescribed treatments without your physician's guidance and approval
It is crucial for healthcare providers to carefully consider these dosages, as compounded medications lack the standardized testing of commercially available products, necessitating vigilant monitoring for efficacy and safety
Key findings from the new analysis indicate: Holistic model helps people stick with their treatment: While dropout rates for commercially available GLP-1s can hover around 80% at six months 2 , only 25% of Hims & Hers customers discontinued treatment in that timeframe, highlighting the strength and confidence a holistic, personalized model delivers
These include: Parkinsons disease Kidney failure or renal disease Diabetes Peripheral nerve damage (neuropathy) Spinal cord injury Iron deficiency Low levels of iron may be a factor in RLS for some people
Based on Phase 2 trial data (Jastreboff et al., NEJM , 2023), the most commonly reported adverse effects of retatrutide include: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (most frequent, particularly during dose escalation) Injection site reactions: Redness, bruising, or mild discomfort Decreased appetite: Generally considered a therapeutic effect but can contribute to nutritional deficiency if severe Increased heart rate: Observed with glucagon receptor agonism
